The firm is an investment firm based in Europe that is developing a growth-focused investment strategy spanning life sciences and professional services. Founded by entrepreneurs with a successful track record of building and exiting a global technology company, the firm seeks to support innovation and long-term business growth through both early-stage venture investments and investments in established businesses. Within life sciences, the firm typically invests up to approximately €500K in Series A financings, with smaller investments at the Seed stage. The firm generally invests alongside other institutional investors through syndicated rounds. 

The firm invests in life science and healthcare companies developing innovative, technology-enabled solutions. Its primary focus is on businesses with scalable, service-oriented or technology-driven business models. While the firm is open to early-stage opportunities, it favors companies that have demonstrated a viable business model and a clear pathway toward commercial scale. 

From a company and management team perspective, the firm seeks founders with compelling value propositions that address meaningful unmet needs. The firm typically participates as a co-investor and provides value beyond capital through its entrepreneurial experience, deep industry expertise, and extensive professional network. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the corporate venture capital arm of a global diversified healthcare and life sciences company with operations spanning food, healthcare, and advanced biological sciences. The firm invests strategically to support innovation across several long-term growth areas, with healthcare serving as a key focus. The firm primarily invests in Seed and Series A companies, committing up to approximately $4M in initial equity investments while reserving capital for follow-on financings. The firm invests globally, with a particular focus on opportunities in North America and Europe. 

The firm is primarily interested in early-stage biotechnology companies developing novel therapeutic platforms and differentiated treatment modalities. The firm is modality-agnostic and evaluates opportunities across small molecules, biologics, antibody-drug conjugates (ADCs), oligonucleotide therapeutics, cell therapies, and gene therapies. Platform technologies are of particular interest. The firm invests in companies from the preclinical through early clinical stages and is generally indication-agnostic, prioritizing highly innovative science with broad strategic potential. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm places the greatest emphasis on novel science and differentiated technology. The firm generally prefers to participate as a co-investor and does not typically seek board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with offices in Western Europe manages multiple life sciences investment funds focused on therapeutics, diagnostics, and medical devices. The firm specializes in early-stage healthcare investments and typically commits approximately €5–12M per portfolio company over multiple financing rounds. The firm primarily invests in European companies and is recognized for its hands-on investment approach and close collaboration with leading academic and clinical research institutions.  

The firm invests across therapeutics, diagnostics, and medical devices, with a primary focus on therapeutics. The firm is modality- and indication-agnostic, evaluating innovative technologies that are approximately 12 months or less from entering the clinic, as well as programs in Phase I and Phase II clinical development. In addition to traditional venture investing, the firm operates as a company builder, collaborating with academic institutions and industrial partners to identify promising scientific discoveries and establish new biotechnology companies.  

From a company and management team perspective, the firm seeks companies with differentiated science and clear value-creation pathways that can achieve strategic exit opportunities within approximately three to five years, often through partnerships or acquisitions by pharmaceutical companies. The firm works closely with founders, academic innovators, and industry partners to accelerate company formation, development, and commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a therapeutics-focused venture builder and investment firm that partners with founders to discover, develop, and advance innovative medicines. The firm supports company creation through direct investments, focused spinouts, and de novo company formation. Combining venture investing with extensive drug discovery and development capabilities, the firm provides hands-on scientific, operational, and strategic support through a large multidisciplinary team of drug discovery experts, development professionals, and company builders. The firm invests through dedicated early- and clinical-stage funds, supporting programs from concept through key preclinical and clinical value-inflection milestones. 

The firm invests exclusively in therapeutics and is agnostic across modalities and disease areas. The firm supports both single-asset and platform companies and is willing to invest across a broad spectrum of maturity, ranging from well-defined scientific concepts to companies with substantial preclinical proof-of-concept or early clinical data. The firm focuses on advancing programs through major development milestones, including preclinical validation, development candidate selection, and clinical demonstration of therapeutic activity. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. Instead, the firm works as a highly collaborative partner, providing scientific, operational, and strategic guidance to help founders optimize development plans, generate high-quality data, and maximize long-term value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage venture capital firm headquartered in Europe and currently investing from its second fund. The firm focuses on startups with proprietary technology and strong global growth potential across deeptech, future of work, fintech, healthtech, and digital health. The firm typically invests in Seed and Series A rounds, generally leading financings while also participating as a syndicate or co-investor when appropriate. Typical investment sizes range from approximately €700K to €1.5M. While the firm invests internationally, companies with connections to the Southeastern European region are viewed favorably.

The firm focuses on healthtech and digital health companies developing software-driven healthcare solutions. The firm is agnostic across healthcare subsectors and disease areas, provided the technology is primarily software-based and demonstrates meaningful innovation, scalability, and commercial potential.

From a company and management team perspective, the firm does not impose strict requirements but values founders with deep domain expertise, strong technological differentiation, and defensible intellectual property. Companies with ties to the Southeastern European ecosystem are considered a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a private investment firm utilizing an asset-centric drug development model to advance early-stage biopharmaceutical programs. Rather than making traditional company-level investments, the firm primarily invests directly in individual therapeutic assets through flexible and innovative transaction structures. The firm can commit up to $25M or more per program, typically funding development through Phase II clinical proof-of-concept before pursuing value realization through licensing or acquisition by larger pharmaceutical companies. The firm invests globally and maintains a concentrated portfolio of high-potential therapeutic programs.

The firm focuses exclusively on biopharmaceutical assets, including small molecules, biologics, and advanced therapeutic modalities such as cell and gene therapies. The firm evaluates opportunities from approximately 12 to 18 months prior to IND through Phase I clinical development, with a preference for IND-ready, patent-protected programs addressing significant unmet medical needs and offering meaningful commercial potential. The firm is indication-agnostic and is open to a broad range of therapeutic areas where proof-of-concept can be established through early clinical studies.

From a company and management team perspective, the firm seeks founders with deep scientific and pharmacological expertise who are committed to a highly collaborative development model. The firm typically partners with lean, experienced teams and integrates each asset into a dedicated development structure while allowing founders to remain actively involved in program leadership. As a hands-on strategic partner, the firm provides extensive drug development expertise, operational resources, and industry relationships to efficiently advance programs through key value-inflection milestones.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a government-backed venture capital firm headquartered in Asia. The firm manages a large growth-stage investment fund while increasingly expanding its focus to earlier-stage innovation with global potential. Typical initial investments are approximately $5M, with the flexibility to deploy substantially larger amounts depending on the opportunity. Although the firm has historically invested primarily in domestic growth-stage companies, it is actively seeking early-stage opportunities globally.

The firm invests across therapeutics, digital therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across all disease areas. The firm generally prefers programs that have entered early clinical development and is less inclined to invest in preclinical-stage assets. Beyond therapeutics, the firm remains open to innovative healthcare technologies with strong commercial and global growth potential. From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm is open to acting as either a lead investor or co-investor and typically seeks board representation when serving as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.